Research Analysts Set Expectations for CELZ FY2024 Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Analysts at Roth Capital upped their FY2024 EPS estimates for Creative Medical Technology in a research note issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($3.19) per share for the year, up from their previous estimate of ($3.29). The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q4 2024 earnings at ($0.63) EPS, FY2025 earnings at ($2.24) EPS, FY2026 earnings at ($2.66) EPS, FY2027 earnings at $3.26 EPS and FY2028 earnings at $6.34 EPS.

Creative Medical Technology Price Performance

Shares of Creative Medical Technology stock opened at $2.52 on Monday. Creative Medical Technology has a 1-year low of $2.47 and a 1-year high of $10.28. The company’s fifty day simple moving average is $3.44 and its 200-day simple moving average is $3.67. The stock has a market capitalization of $4.41 million, a PE ratio of -0.68 and a beta of 2.01.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC lifted its stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,570 shares of the company’s stock after buying an additional 3,170 shares during the quarter. Aaron Wealth Advisors LLC owned about 1.45% of Creative Medical Technology worth $75,000 as of its most recent filing with the Securities & Exchange Commission. 1.42% of the stock is owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.